Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 7;10(22):5608-5613.
doi: 10.7150/jca.30731. eCollection 2019.

Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients

Ting-Ting Lin  1 , Ye-Hui Chen  1 , Yu-Peng Wu  1 , Shao-Zhan Chen  1 , Xiao-Dong Li  1 , Yun-Zhi Lin  1 , Shao-Hao Chen  1 , Qing-Shui Zheng  1 , Yong Wei  1 , Ning Xu  1 , Xue-Yi Xue  1
Affiliations

Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients

Ting-Ting Lin et al. J Cancer. .

Abstract

Purpose: To investigate the risk factors for progression to castration-resistant prostate cancer (CRPC) in metastatic prostate cancer (mPCa) patients who underwent androgen deprivation therapy (ADT). Methods: We analyzed 216 patients with mPCa who underwent ADT between January 2006 and December 2015 at the First Affiliated Hospital of Fujian Medical University. Univariate and multivariate Cox regression analysis were used to explore the risk factors for progression to CRPC. Kaplan-Meier analysis and log-rank test were used to evaluate the difference in progression-free survival (PFS). Results: A total of 121 (56.0%) patients who underwent ADT showed progression to CRPC. Multivariate Cox regression analysis demonstrated that Gleason grade group, prostate-specific antigen nadir (nPSA), and time to PSA nadir (TTN) were risk factors for progression to CRPC in mPCa patients. Kaplan-Meier analysis demonstrated that patients in Gleason grade group ≥3, nPSA >0.2 ng/ml and TTN <6 months had shorter PFS. Conclusion: This study demonstrated that Gleason grade group, nPSA and TTN were risk factors for progression to CRPC. Patients with higher Gleason grade group, higher nPSA and shorter TTN have shorter PFS and higher risk of progression to CRPC after ADT.

Keywords: androgen deprivation therapy; castration-resistant prostate cancer; metastatic prostate cancer; progression-free survival; risk factors.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
Kaplan-Meier analysis for progression-free survival in patients with advanced prostate cancer underwent androgen deprivation therapy.
Figure 2
Figure 2
Kaplan-Meier analysis for progression-free survival in patients with advanced prostate cancer underwent androgen deprivation therapy stratified by Gleason grade group.
Figure 3
Figure 3
Kaplan-Meier analysis for progression-free survival in patients with advanced prostate cancer underwent androgen deprivation therapy stratified by nadir PSA.
Figure 4
Figure 4
Kaplan-Meier analysis for progression-free survival in patients with advanced prostate cancer underwent androgen deprivation therapy stratified by time to nadir PSA.
See this image and copyright information in PMC

References

    1. Amato R, Stepankiw M, Gonzales P. A phase II trial of androgen deprivation therapy (ADT) plus chemotherapy as initial treatment for local failures or advanced prostate cancer. Cancer Chemother Pharmacol. 2013;71(6):1629–34. - PubMed
    1. Briganti A, Suardi N, Gallina A, Abdollah F, Novara G, Ficarra V. et al. Predicting the risk of bone metastasis in prostate cancer. Cancer Treat Rev. 2014;40(1):3–11. - PubMed
    1. Ciccarese C, Massari F, Iacovelli R, Fiorentino M, Montironi R, Di Nunno V. et al. Prostate cancer heterogeneity: Discovering novel molecular targets for therapy. Cancer Treat Rev. 2017;54:68–73. - PubMed
    1. Daniyal M, Siddiqui ZA, Akram M, Asif HM, Sultana S, Khan A. Epidemiology, etiology, diagnosis and treatment of prostate cancer. Asian Pac J Cancer Prev. 2014;15(22):9575–8. - PubMed
    1. Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB. Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers. Eur Urol. 2018;73(4):560–569. - PubMed